Vilin Bio Med Ltd Stock Price Today (NSE: VILINBIO)
Fundamental Score
Vilin Bio Med Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vilin Bio Med Ltd share price today is ₹46.80, up +0.00% on NSE/BSE as of 19 June 2026. Vilin Bio Med Ltd (VILINBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹29.58 (Cr). The 52-week high for VILINBIO share price is ₹54.40 and the 52-week low is ₹18.95. At a P/E ratio of 118.30x, VILINBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.96% and a debt-to-equity ratio of 0.02.
Vilin Bio Med Ltd Share Price Chart — NSE/BSE Historical Performance
Vilin Bio Med Ltd share price chart: 29.43% return over the past month. 52-week high ₹54.40, 52-week low ₹18.95.
Vilin Bio Med Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹46.80 | ₹47.45 | ₹45.70 | ₹46.80 | 60.00K (Cr) | |
| ₹46.55 | ₹46.55 | ₹46.55 | ₹46.55 | 8.00K (Cr) | |
| ₹47.50 | ₹47.50 | ₹47.50 | ₹47.50 | 0.00 (Cr) | |
| ₹47.50 | ₹47.50 | ₹47.50 | ₹47.50 | 0.00 (Cr) | |
| ₹47.50 | ₹47.50 | ₹47.50 | ₹47.50 | 4.00K (Cr) | |
| ₹47.60 | ₹47.60 | ₹47.55 | ₹47.60 | 20.00K (Cr) | |
| ₹48.50 | ₹48.50 | ₹48.50 | ₹48.50 | 0.00 (Cr) | |
| ₹48.50 | ₹48.50 | ₹48.50 | ₹48.50 | 0.00 (Cr) | |
| ₹48.50 | ₹48.50 | ₹48.50 | ₹48.50 | 4.00K (Cr) | |
| ₹49.40 | ₹49.40 | ₹49.40 | ₹49.40 | 0.00 (Cr) |
Vilin Bio Med Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹46.80 | ₹47.45 | ₹45.70 | ₹46.80 | +0.00% | |
| ₹40.15 | ₹54.40 | ₹39.00 | ₹46.55 | +15.94% | |
| ₹37.30 | ₹38.85 | ₹36.60 | ₹38.85 | +4.16% | |
| ₹33.25 | ₹38.30 | ₹32.00 | ₹36.65 | +10.23% | |
| ₹38.40 | ₹38.40 | ₹29.40 | ₹34.95 | -8.98% | |
| ₹19.95 | ₹35.00 | ₹19.95 | ₹35.00 | +75.44% | |
| ₹21.20 | ₹21.20 | ₹18.95 | ₹20.95 | -1.18% | |
| ₹25.30 | ₹26.55 | ₹20.20 | ₹20.20 | -20.16% | |
| ₹24.75 | ₹27.95 | ₹24.00 | ₹26.45 | +6.87% | |
| ₹26.90 | ₹27.25 | ₹23.40 | ₹25.80 | -4.09% | |
| ₹27.55 | ₹28.50 | ₹23.50 | ₹26.90 | -2.36% | |
| ₹26.45 | ₹27.55 | ₹24.50 | ₹27.55 | +4.16% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Micro-cap pharma play trading at nosebleed valuations with zero FII/DII interest; avoid.
WHAT'S HAPPENING NOW
No major catalysts found after live search. Recent news is dominated by broader pharma sector trends, like FDA approvals for Aurobindo and Alembic, and discussions around US pharma tariffs. Vilin Bio Med specific news is absent.
CORE STORY
Micro-cap pharma play trading on hope, not current earnings. Market likely pricing an eventual ramp-up in sales after a strong YoY sales figure in the latest quarter.
- Latest quarter sales growth of 115.14%
- Low debt/equity ratio of 0.02
- Pharma sector tailwinds
- Significant order wins
- Consistent sales growth for next 2 quarters
- Positive free cash flow
- Micro-cap liquidity risk
- Expensive valuation P/E 118.3x vs industry P/E 31.77x
- Negative free cash flow of ₹-11.25 Cr over 5 years
Zero FII/DII interest (0.0%). Promoter holding steady at 63.89%.
Pharma sector seeing tailwinds with increased salaries and FDA approvals for generics, but US tariff risks linger.
No - Free Cash Flow 5Y: ₹-11.25 Cr
If sales growth doesn't translate to free cash flow, the stock is toast. Watch next two quarters closely.
Primary Thesis Risk
Inability to convert sales growth into positive free cash flow will lead to a collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vilin Bio Med Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vilin Bio Med Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VILINBIO across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (25.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (115.14%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (63.89%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (0.96%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.20%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 118.30x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-2.28% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-20.12% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Weak Interest Coverage (1.69x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-11.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vilin Bio Med Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vilin Bio Med Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
33.7/100 | ₹46.80₹47 | ₹29.58₹29.58 | 118.30Average 118.3 Average | 0.96%Poor 0.96% Poor | 4.20%Poor 4.20% Poor | 0.02Excellent 0.0 Excellent | 6.58%Good 6.58% Good | -2.28%Poor -2.28% Poor | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Vilin Bio Med Ltd PE Ratio History
Historical price-to-earnings ratio for VILINBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹0.89 | ₹23.30 | 26.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vilin Bio Med Ltd Quarterly Performance
Latest quarterly metrics for VILINBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
115.14%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
25.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-2.28%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
6.58%
Compounded annual net profit growth over 5 years
Vilin Bio Med Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VILINBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vilin Bio Med Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vilin Bio Med Ltd (VILINBIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vilin Bio Med Ltd
About VILINBIO (Vilin Bio Med Ltd)
Vilin Bio Med Ltd (VILINBIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a curr...ent market capitalisation of ₹29.58 (Cr). Vilin Bio Med Ltd has delivered a Return on Equity (ROE) of 0.96% and a ROCE of 4.20%. The debt-to-equity ratio stands at 0.02, reflecting the company's capital structure. Investors tracking VILINBIO share price can monitor key metrics including P/E ratio, promoter holding of 63.89%, and quarterly earnings growth.
Company Details
VILINBIO Share Price: Frequently Asked Questions
What is the current share price of Vilin Bio Med Ltd?
Vilin Bio Med Ltd (VILINBIO) trades at ₹46.80 on NSE. Market cap ₹29.58 (Cr). Educational data only.
What is the P/E ratio of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has a P/E of 118.30x vs industry average 31.77x.
What is the Bull Run score for Vilin Bio Med Ltd?
Vilin Bio Med Ltd has a Bull Run score of 33.7/100 based on 25+ financial parameters.
Does Vilin Bio Med Ltd pay dividends?
Vilin Bio Med Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has ROE of 0.96%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vilin Bio Med Ltd?
Vilin Bio Med Ltd has debt-to-equity of 0.02.
Is Vilin Bio Med Ltd a good investment?
Bull Run gives Vilin Bio Med Ltd a score of 33.7/100. This is not investment advice — consult a SEBI-registered advisor.